QuarterHawk — Equity ResearchQuarterHawk — Equity Research

OrthoPediatrics Corp. (KIDS)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
3

Bullish pullback-to-support limit entry: buy 22.05 GTC (retest of the 09-21 VWAP 22.08 / 22.00 support, below the last close 22.35) with a structure-based stop at 21.11 (pullback ATR floor = 1.0xATR, below the triple-tested 21.56-21.58 shelf), targets 23.93 and 25.34, R/R 2.00. A breakout stop above the settled 09-21 high 22.48 was evaluated and rejected: it would chase a two-session bounce with the MACD line below zero and ADX 20, while the dip-buy enters on the retest of support.

Analysis as of 2026-09-22· more than 2 trading days ago

Company overview

OrthoPediatrics Corp. is a medical technology company focused on developing and commercializing orthopedic implants and devices for children. Their products address trauma, deformity correction, spinal deformities, and sports medicine, serving pediatric orthopedic surgeons globally. Founded in 2006, the company is headquartered in Warsaw, Indiana.

Fundamental

fair
Fundamental3
Mixed fundamentals

Strong growth and high gross margins are offset by persistent net losses and negative free cash flow.

Strong top-line growth and high gross margins, but still loss-making: FY2025 revenue was $236.3M (about +15% YoY) with ~73% gross margin, yet net margin was about -16.8% and free cash flow was negative. The latest 10-Q shows continued growth and improved operating cash burn, while liquidity remains comfortable (current ratio ~4.8; cash & short-term investments ~$45.9M) and management states it is compliant with debt covenants. Overall: attractive growth profile, but the profitability/FCF turnaround is still the key uncertainty.

Sentiment

fair
Sentiment3
Mixed sentiment

Positive corporate developments are counterbalanced by insider selling and a lack of retail interest.

Dominant near-term catalyst is KIDS's addition to the S&P Healthcare Equipment Select Industry Index (technical, announced, 2026-09-21), offset by a director/10%-owner selling ~$6.35M of stock on 2026-09-10; the sentiment delta is indeterminate (sparse baseline, 2 scored items) and retail velocity is indeterminate; a moderate red-flag cap applies for conflicting in-window catalyst signals.

Technical

fair
Technical3
Bullish pullback

A pullback within an uptrend presents a structured buying opportunity with support at $21.56-$21.67.

Pullback within an intact intermediate uptrend: price 22.35 sits above the rising SMA50 (22.25) and far above the SMA200 (18.76) after a ~19% correction from the 08-20 high (26.74). A support shelf at 21.56-21.67 has held three tests (09-17, 09-18, 09-21 lows) and the last two sessions closed progressively higher off it (21.82, then 22.35 near the session high). Momentum is mixed rather than confirmed: RSI 47.4 has recovered from the 37 zone, the MACD histogram has been improving for seven sessions (-0.48 to -0.15), but the MACD line is still below zero (-0.19, below its signal) and ADX 20.1 shows no established trend. Short-term averages (SMA20 22.84, EMA21 22.67, EMA9 22.37) remain overhead, so this is a dip-buy with structure, not a confirmed reversal. Volume is healthy: recent 3-session dollar volume ~$5.85M exceeds the 20-day average ~$5.16M. Score 3 (mixed with a bullish structural bias).

You’re looking at 2026-09-22 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.